Sign In
Buy ETNB
$14.84
+0 (+0%)
At Close: Jan 29, 2026
89bio (ETNB) Up 25% on Upbeat Data From Mid-Stage NASH Study
03:14pm, Thursday, 23'rd Mar 2023
Data from a phase IIb study showed that treatment with 89bio's (ETNB) lead candidate improved fibrosis improved fibrosis at 3.5 times the rate of the placebo without worsening NASH.
Biotech Stock Surges on Mid-Stage Drug Trial Success
10:49am, Wednesday, 22'nd Mar 2023
The shares of 89bio Inc ( NASDAQ:ETNB) are up 38.2% to trade at $15.11 at last check, after the biotech name revealed its experimental drug pegozafermin to treat nonalcoholic steatohepatitis (NASH)
Why Is 89bio (ETNB) Stock Up 34% Today?
09:30am, Wednesday, 22'nd Mar 2023
89bio (NASDAQ: ETNB ) stock is taking off on Wednesday after the company posted results from a Phase 2b clinical trial. The goal of this study is to determine the effectiveness of pegozafermin in trea
89bio Rockets 30% — And Akero Dives — On A Scorching Battle In Liver Disease
09:14am, Wednesday, 22'nd Mar 2023
Small biotech company 89bio scored a win Wednesday in fatty liver disease, and ETNB stock rocketed well above its 50-day moving average. The post 89bio Rockets 30% — And Akero Dives — On A Scorchi
89bio's stock rallies 48% on new NASH data
07:55am, Wednesday, 22'nd Mar 2023
Shares of 89bio Inc. ETNB, -7.06% soared about 48% in premarket trading on Wednesday after the company said its experimental treatment for nonalcoholic steatohepatitis (NASH) led to NASH resolution co
89Bio: A Promising NASH Innovator
06:18pm, Friday, 17'th Mar 2023
As pegozafermin has a differentiated mode of action from Madrigal's resmetirom, 89bio, Inc. can offer an intriguing solution for NASH. Early pegozafermin data showed extremely strong liver fat reducti
Wall Street Analysts See an 80% Upside in 89BIO (ETNB): Can the Stock Really Move This High?
11:28am, Wednesday, 15'th Mar 2023
The mean of analysts' price targets for 89BIO (ETNB) points to an 80% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in
4 Best Breakout Stocks to Buy for Superb Returns
09:02am, Friday, 24'th Feb 2023
Coty (COTY), OneSpaWorld (OSW), Mueller Water Products (MWA) and 89BIO (ETNB) have been selected as the breakout stocks for today.
SAN FRANCISCO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the
TEVA Beats Q4 Earnings Estimates, Sales Miss & Stock Down
09:48am, Thursday, 09'th Feb 2023
TEVA reports mixed Q4 results, beating earnings estimates, while sales slightly miss estimates. Stock down post earnings release.
Orbimed Advisors Reduces Position in 89bio
10:27pm, Friday, 27'th Jan 2023
Fintel reports that Orbimed Advisors Llc has filed a 13D/A form with the SEC disclosing ownership of 1.50MM shares of 89bio Inc (ETNB).
89BIO (ETNB) Upgraded to Strong Buy: What Does It Mean for the Stock?
01:33pm, Tuesday, 17'th Jan 2023
89BIO (ETNB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
89Bio: Let's Not Give Up Already
08:34am, Thursday, 22'nd Dec 2022
ETNB went down after Madrigal's success. It has a NASH molecule with a different mechanism of action.
89bio to Participate in the H.C. Wainwright 6th Annual NASH Investor Conference
08:00am, Thursday, 13'th Oct 2022
SAN FRANCISCO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the
89bio to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
08:00am, Wednesday, 07'th Sep 2022
SAN FRANCISCO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for th
